SCHEMBL5565862

SCHEMBL5565862

CSC(=O)C(c1ccccc1)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
MAPT P10636 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
HDAC3 O15379 1/20 0.48
HDAC4 P56524 1/20 0.48
HDAC1 Q13547 1/20 0.48
HDAC7 Q8WUI4 1/20 0.48
HDAC2 Q92769 1/20 0.48
HDAC10 Q969S8 1/20 0.48
HDAC11 Q96DB2 1/20 0.48
HDAC8 Q9BY41 1/20 0.48
HDAC6 Q9UBN7 1/20 0.48
HDAC9 Q9UKV0 1/20 0.48
HDAC5 Q9UQL6 1/20 0.48
CTSD P07339 1/20 0.47
CYP2D6 P10635 1/20 0.44
SRC P12931 1/20 0.44
KMT2A Q03164 4/20 0.43
MEN1 O00255 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2328390 0.81 TDP1 (0.54) POLBL3MBTL1MAPTTDP1HDAC3
SCHEMBL5094452 0.80 PTGS2 (0.48) POLBMAPTCYP2D6SRCLMNA
SCHEMBL7309314 0.78 CYP2D6 (0.41) POLBMAPTCYP2D6SRCKMT2A
SCHEMBL25858677 0.78 LMNA (0.42) CYP2D6SRCLMNAMAPK1
SCHEMBL2328394 0.77 TDP1 (0.50) POLBL3MBTL1MAPTTDP1HDAC3
SCHEMBL7367258 0.77 SRC (0.50) POLBMAPTCYP2D6SRCKMT2A
SCHEMBL27791494 0.75 LMNA (0.55) POLBMAPTHDAC3HDAC4HDAC1
SCHEMBL13316976 0.74 ATM (0.41) L3MBTL1CYP2D6SRCKMT2AMEN1
SCHEMBL396389 0.73 L3MBTL1 (0.56) POLBL3MBTL1TDP1HDAC3HDAC4
Diphenylacetic Acid SCHEMBL11774892 0.73 SRC (0.56) POLBL3MBTL1TDP1HDAC3HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103980169-A Synthetic method of modafinil HEBEI KANGTAI PHARMACEUTICAL CO LTD 2014-08-13 CN disclosed
US-20130203709-A1 ACYLSULFONAMIDES AND PROCESSES FOR PRODUCING THE SAME THE PENN STATE RESEARCH FOUNDATION (US) 2013-08-08 US disclosed
CN-101440053-B Preparation of benzhydryl thioacetamide CHONGQING KANGLE PHARMACEUTICAL CO LTD 2013-04-03 CN disclosed
CN-100534979-C Synthesis method of modafinil ZHEJIANG HUANA PHARMACEUTICAL (CN) 2009-09-02 CN disclosed
CN-101440053-A Preparation of benzhydryl thioacetamide CHONGQING KANGLE PHARMACEUTICA (CN) 2009-05-27 CN disclosed
CN-1986527-A Novel method for synthesizing modafinil ZHEJIANG HUANA PHARMACEUTICAL (CN) 2007-06-27 CN disclosed
US-7211684-B2 Method for preparing methyl 2-diphenylmethylsulfinylacetate CEPHALON FRANCE (FR) 2007-05-01 US disclosed
US-20060235237-A1 Method for preparing methyl 2-diphenylmethylsulfinylacetate TEVA SANTE (FR) 2006-10-19 US disclosed
EP-1583739-A1 METHOD FOR PREPARING METHYL 2-DIPHENYLMETHYLSULFINYLACETATE Organisation de Synthese Mondiale Orsymonde (FR) 2005-10-12 EP disclosed
WO-2004063149-A1 METHOD FOR PREPARING METHYL 2-DIPHENYLMETHYLSULFINYLACETATE ORGANISATION DE SYNTHESE MONDIALE ORSYMONDE (FR) 2004-07-29 WO disclosed
EP-1437345-A1 Novel method for preparing methyl 2-diphenylmethylsulfinylacetate Organisation de Synthese Mondiale Orsymonde (FR) 2004-07-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060235237-A1 Method for preparing methyl 2-diphenylmethylsulfinylacetate MTR, TST, MSMO1 POLB 682/4885L3MBTL1 2257/4885MAPT 2741/4885
US-20130203709-A1 ACYLSULFONAMIDES AND PROCESSES FOR PRODUCING THE SAME BCL2, BCL2L2, BCL6 POLB 4401/4885L3MBTL1 2010/4885MAPT 4326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.